H.C. Wainwright raised the firm’s price target on Lyell Immunopharma (LYEL) to $20 from $10 and keeps a Neutral rating on the shares. The firm added colorectal cancer to the company’s valuation.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LYEL: